Antibiotic Incentive Legislation: Can Reimbursement Horn In?
This article was originally published in RPM Report
Executive Summary
There are two antibiotic incentive bills vying for attention in Congress. One is a follow-on to the popular GAIN Act; the other takes a new path – creating generous reimbursement formulas to help the next wave of anti-infectives find a successful niche in hospital market.
You may also be interested in...
Antibiotic Incentives Moving Forward: “Cures” Act Pathway May Apply More Broadly
Anti-infective drug development companies appear set to receive another round of legislative incentives as the “Cures” process moves forward. The only question is when and how much they will receive. One provision—creating a new limited use pathway—could be important for all classes of drug development.
Doubling Down On Antibiotic Incentives: Congress, Obama Administration Drafting Proposals
The 2012 FDA Safety & Innovation Act included important new incentives for antibiotic developers. But the Obama Administration and key legislators want to do even more to revive R&D in the space. What will it take to bring Big Pharma back?
2020 Antibiotic Goal in Jeopardy? HHS Analysis Shows Need For Earlier, Larger Incentives
Goal of 10 new antibiotics by 2020 may be unlikely given current marketplace for antibiotics, some experts predict as a new study shows recent proposals to revive development may be focused at wrong point in development timeline. Study suggests need for large increases in government funding.